Navigation Links
New Migraine Drug Shows Promise
Date:8/14/2009

Orally inhaled therapy effective with few side effects, study finds

FRIDAY, Aug. 14 (HealthDay News) -- An experimental inhaled drug called Levadex is an effective treatment for migraines, according to a drug company-funded study.

The phase III trial, conducted at the Jefferson Headache Center at Thomas Jefferson University Hospital in Philadelphia, found that migraine patients who took the drug had greater relief from symptoms such as pain, nausea and light/sound sensitivity than those who took a placebo.

The drug provided pain relief within 30 minutes and sustained relief for 48 hours in patients with moderate or severe migraines. There were no drug-related, serious adverse effects, according to a news release issued by the university.

"The major advantage of Levadex is that it has the efficacy of intravenous DHE (dihydroergotamine) with a side-effect profile similar to placebo and better than oral triptans," Dr. Stephen Silberstein, director of the Jefferson Headache Center, and professor in the neurology department at Jefferson Medical College, said in the news release.

The study was funded by MAP Pharmaceuticals, Inc. Silberstein serves on the advisory board of the company.

More information

The American Academy of Family Physicians has more about migraine.



-- Robert Preidt



SOURCE: Thomas Jefferson University, news release, Aug. 11, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1

Related medicine news :

1. Neuromuscular Dentistry Ends Womans Migraines
2. Migraine Tied to Thickening in Brain Area
3. Business Coalition Honors BlueChoice HealthPlan for Migraine Program
4. The HealthCentral Network Wins eHealthcare Awards for Breast Cancer and Migraine Web Sites
5. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
6. Comatose locusts may help relieve migraines
7. Epilepsy Drug Doesnt Prevent Migraines
8. MyMigraineConnection.com and Migraine Expert Teri Robert Announce Seventh Annual Migraine and Headache Poetry Contest
9. Migraines Frequency Influences Heart Attack, Stroke Risk
10. Overuse of Opioids, Barbiturates Boosts Chronic Migraine Risk
11. Skin Pain, Sensitivity Rises With Migraine
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Migraine Drug  Shows Promise
(Date:2/10/2016)... York, NY (PRWEB) , ... February 10, 2016 , ... ... campaign to celebrate and raise awareness of Nestlé KITKAT as the first global confectionery ... the lives of cocoa farmers and the quality of their product, through activities that ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a full-service health care communications company offering education, research and medical media, ... practitioners and specialists working in infectious diseases. , As the all-inclusive resource ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop CEO Jay ... 2.0 version at the International Roofing Expo in Orlando, Florida on February 17-19. ... most advanced weather technology in the hands of consumers, roofing contractors, manufacturers and ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... ... February 10, 2016 , ... Compliancy Group LLC is pleased ... professionals throughout the country. The Guard was specifically designed to handle each element ... training, regulatory updates, and compliance coaching. , In addition to meeting the compliance ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Feb. 10, 2016  Fotona, based in the U.S. and ... its new ST PRO Lightwalker dental laser at the upcoming ... from 25-27 February, 2016 in booth #4815. The ST PRO ... with many of the features of the award winning, industry ... PRO competitive price will be very attractive to many dentists ...
(Date:2/10/2016)... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), today ... and full year ended December 31, 2015. ... transformational year for Vanda with the continued growth of ... of HETLIOZ for Non-24," said Mihael H. Polymeropoulos, M.D., ... our U.S. product portfolio builds on this success and ...
(Date:2/10/2016)... report from business intelligence provider GBI Research - Alzheimer,s Disease Therapeutics Market ... double from just under $5 billion in 2014 to an estimated $10.4 billion ... Canada , France , Germany ... and Japan , and will primarily be driven by increased ... France , Germany , Italy ...
Breaking Medicine Technology: